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Abstract
Background
Although Iran is reported to be an endemic country for hepatitis E virus (HEV), data on the
prevalence of HEV infection among pregnant women are scarce and the epidemiology of
HEV is unknown in most parts of the country. Therefore, this study was conducted to eluci-
date the prevalence, risk factors and genotypic pattern of HEV infection among pregnant
women resident in the northern shores of Persian Gulf. This is the first report on the epidemi-
ology of HEV infection among pregnant women in this territory.
Methods
From October 2016 to May 2017, 1331 pregnant women participated in this study. The
mean age ± SD of participants was 27.93±5.7 years with a range of 14–45 years. Serum
samples of pregnant women were screened for the presence of anti-HEV total antibodies,
anti-HEV IgG and anti-HEV IgM using commercially available ELISA kits (DIA.PRO, Milan,
Italy). All anti-HEV IgG and anti-HEV IgM positive samples were tested for HEV RNA using
two independent reverse transcriptase polymerase chain reaction (RT-PCR) assays, target-
ing ORF2 and ORF3 of HEV genome. In addition, 92 anti-HEV seronegative samples as
well as 50 pooled seronegative samples were evaluated by two independent RT-PCR
assays for validation of results.
Results
Of the 1331 pregnant women, 84 women (6.3%, 95% CI: 5.1%-7.7%) were positive for anti-
HEV antibodies, of which 83 women had anti-HEV IgG, and 11 women (0.83%, 95% CI:
0.47%-1.47%) had anti-HEV IgM. The highest rate of HEV seroprevalence was observed
among Afghan immigrants (68.0%), uneducated pregnant women (46.51%) and those
PLOS ONE | https://doi.org/10.1371/journal.pone.0191090 January 12, 2018 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Farshadpour F, Taherkhani R, Ravanbod
MR, Eghbali SS, Taherkhani S, Mahdavi E (2018)
Prevalence, risk factors and molecular evaluation of
hepatitis E virus infection among pregnant women
resident in the northern shores of Persian Gulf,
Iran. PLoS ONE 13(1): e0191090. https://doi.org/
10.1371/journal.pone.0191090
Editor: Jason Blackard, University of Cincinnati
College of Medicine, UNITED STATES
Received: August 23, 2017
Accepted: November 29, 2017
Published: January 12, 2018
Copyright: © 2018 Farshadpour et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This study was supported financially by
the Deputy Research and Affairs of Bushehr
University of Medical Sciences with grant number
3253. The funder had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
residents in Bushehr city (8.75%). All anti-HEV IgG and/or IgM positive samples were found
to be negative for HEV RNA. In addition, all of the evaluated anti-HEV seronegative samples
were negative for HEV RNA. HEV seropositivity among pregnant women was statistically
associated with age, ethnicity, place of residence, number of pregnancies, and level of edu-
cation. So that, low education levels, Afghan, residence in Bushehr city, age group >34
years, and more parities were risk factors for exposure to HEV. In contrast, HEV seropositiv-
ity was not associated with stage of gestation, history of abortion, and time of sampling.
Conclusion
The northern shores of Persian Gulf in Iran, with HEV seroprevalence of 6.3%, can be clas-
sified as an endemic geographical region for hepatitis E, and residents of Bushehr city,
Afghan immigrants and uneducated women are the main at-risk populations in this territory.
Introduction
Hepatitis E virus (HEV), a member of the family Hepeviridae, is characterized by an acute self-
limited or asymptomatic course in the host. HEV is known to cause large outbreaks. Compli-
cations are usually self-limiting, and the treatment is mainly supportive [1, 2]. Although Hepa-
titis E outbreaks have mostly been described in developing countries so far, the virus is already
known to circulate in developed countries as silent infection [2, 3]. HEV is usually acquired
through consumption of contaminated food or water. In addition to faecal-oral route, organ
transplantation, blood transfusion, hemodialysis and sexual intercourse are some other possi-
ble ways of HEV transmission [4, 5].
Clinical presentations of HEV infection are minimal in the general population but can lead
to life-threatening conditions in immunocompromised patients, pregnant women, organ
transplant recipient patients and those with underlying liver problems [4]. The maternal mor-
tality rate of HEV infection during pregnancy can reach to 20–25% accompanying with prena-
tal or neonatal complications such as stillbirth, miscarriage, death after birth, premature birth,
and jaundice [2]. Such complications are well known trigger of HEV infection during preg-
nancy, however, little is known about the underlying pathomechanisms. Progression to such
severe complications during pregnancy seems to be the consequence of direct or indirect cyto-
pathic effects of HEV through immune-mediated pathogenesis. The pregnancy-related
changes in immunological and hormonal responses have also a profound effect on the patho-
genesis of HEV. Further studies are needed to shed more light on the underlying mechanisms
[1, 6].
The importance of HEV infection during pregnancy as a health dilemma is well known, but
most of the time this importance is neglected maybe due to anomalous observations on hepati-
tis E complications among pregnant women in different parts of the world [7]. To reach a gen-
eral consensus on this infection during pregnancy, HEV surveillance in all parts of the world is
needed in order to provide appropriate public health recommendations. Although Iran is
reported to be an endemic country for HEV, data on the prevalence of HEV infection among
pregnant women in Iran are scarce and the epidemiology of HEV is unknown in most parts of
the country [8, 9]. Therefore, this study was conducted to elucidate the prevalence, risk factors
and genotypic pattern of HEV infection among pregnant women in South of Iran, the north-
ern shores of Persian Gulf. This is the first report on the epidemiology of HEV infection
among pregnant women in this territory.
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Material and methods
Study setting and population
This descriptive cross-sectional study was funded by Bushehr University of Medical Sciences
through research grant number 3253. From October 2016 to May 2017, the population-based
sample of pregnant women from Bushehr province was collected randomly using the multi-
stage cluster sampling method. Bushehr is a large province in the northern shores of Persian
Gulf, which consists of 10 cities with different ethnicities including Fars, Arab and Turk. In
addition, a huge number of Afghan immigrants are resident in this region.
In the first stage, four of the most populated cities of this territory, including Bushehr, Bor-
azjan, Ahram and Jam were selected randomly. In the next stage, two public health centers
were selected randomly from each city. In the mentioned time period, consecutive pregnant
women attending these public health centers for routine gynecological screening were enrolled
in this study. A questionnaire containing demographic information of age, place of residence,
ethnicity, stage of gestation, number of pregnancy, history of abortion, level of education and
time of sampling was completed for each participant. In addition, all pregnant women were
requested to give a written informed consent to use their leftover serum samples for HEV
detection and use of test results for analysis. The ethical committee of Bushehr University of
Medical Sciences approved this study (reference no. IR.BPUMS.Rec.1395.47). The records of
all participants were analyzed in an anonymous way with respect to the results of serological
screening for HEV infection.
Laboratory diagnosis
Serum samples of pregnant women who gave written informed consent were screened for the
presence of anti-HEV total antibodies, anti-HEV IgG and anti-HEV IgM using commercially
available ELISA kits (HEV Ab ELISA kit, HEV IgG ELISA kit and HEV IgM ELISA kit, DIA.
PRO, Milan, Italy). The specificity of the HEV Ab, HEV IgM and HEV IgG DIA.PRO ELISA
kits was> 99.5%, > 95% and> 99.5%, respectively, and the sensitivity of these kits was 100%.
In addition, the DIA.PRO ELISA had high concordance compared with the in-house ELISA
[10]. All anti-HEV IgG and anti-HEV IgM positive samples were tested for HEV RNA using
two independent reverse transcriptase polymerase chain reaction (RT-PCR) assays. In addi-
tion, 92 anti-HEV seronegative samples as well as 50 pooled seronegative samples were evalu-
ated by two independent RT-PCR assays for validation of results. Two hundred seronegative
samples were combined into pools of 4 using 50μl of each sample. First, the samples were sub-
jected to an in house nested RT-PCR, targeting ORF2/ORF3 of HEV genome. Briefly, HEV
RNA was extracted from serum samples using High Pure Viral Nucleic Acid kit (Roche,
Mannheim, Germany) and was immediately reverse-transcribed into cDNA using SuperScript
III cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Then, cDNA was amplified by nested RT-PCR using outer primers [forward
primer (HE361): GCRGTGGTTTCTGGGGTGAC; reverse primer (HE364): CTGGGMYTGGTCD
CGCCAAG] and inner primers [forward primer (HE366): GGGYTGATTCTCAGCCCTTCGC;
reverse primer (HE363): GMYTGGTCDCGCCAAGHGGA].
The samples were further tested using another nested RT-PCR. The following sets of nested
primers were used to amplify 731 nucleotides and 348 nucleotides of the ORF2 region, respec-
tively: outer primers [forward primer (3156N): AATTATGCYCAGTAYCGRGTTG;reverse
primer (3157N): CCCTTRTCYTGCTGMGCATTCTC] and inner primers [forward primer
(3158N): GTWATGCTYTGCATWCATGGCT; reverse primer (3159N): AGCCGACGAAATCAAT
TCTGTC]. The sequences of primers, regions in genome and PCR conditions for detection of
Hepatitis E virus infection among pregnant women in Iran
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HEV RNA are summarized in Table 1. The amplified 348 bp length fragment was then submit-
ted for sequencing to determine HEV genotypes. Precise procedures and protocols were taken
into consideration in order to avoid potential carry-over contaminations in the cDNA synthe-
sis and PCR reactions [11]. In addition, negative and positive controls were included in each
round of PCR to validate results.
Statistical analysis
SPSS 17 package program (SPSS Inc., Chicago, IL, USA) was used to perform all statistical
analyses, and P values of less than 0.05 were defined statistically significant. Data were pre-
sented as frequencies, percentage and mean ± standard deviation (SD) following analysis by
descriptive statistics. Quantitative data were compared between HEV seropositive and HEV
seronegative pregnant women by Student’s t-test. Chi-square test or Fisher’s exact test was
used to compare and analyze categorical data. To evaluate the effect of variables on HEV sero-
positivity and to identify the risk factors of HEV infection in pregnant women, logistic regres-
sion analysis was used, and odds ratio (OR) with 95% confidence intervals (CI) was calculated.
Result
During the study period, 1331 pregnant women participated in this study. The mean age ± SD
of participants was 27.93±5.7 years with a range of 14–45 years. The pregnant women were
classified into five age groups: <20, 20–24, 25–29, 30–34 and over 34 years. The majority of
pregnant women were in the age group 25–29 years (34.9%), third trimester of pregnancy
(54.0%), as well as Fars (83.3%) and educated. Of the 1331 pregnant women, 84 women (6.3%,
95% CI: 5.1%-7.7%) were positive for anti-HEV antibodies, of which 83 women had anti-HEV
IgG, and 11 women (0.83%, 95% CI: 0.47%-1.47%) had anti-HEV IgM. All anti-HEV IgM
seropositive samples were positive for anti-HEV IgG except one sample, which was positive
for anti-HEV IgM and negative for anti-HEV IgG. All anti-HEV IgG and/or IgM positive sam-
ples were found to be negative for the presence of HEV RNA. In addition, all of the evaluated
anti-HEV seronegative samples were negative for HEV RNA. Regarding the pregnancy out-
come, all pregnant women had successful childbirth except eight seronegative pregnant
women. These eight women had spontaneous abortion. Nevertheless, these women were nega-
tive for HEV RNA despite experiencing abortion.
When we evaluated the seroprevalence of HEV in the age groups, the highest rate of anti-
HEV seroprevalence was found in the age group >34 years (11.76%) followed by the age
group 20–24 years (8.74%), while pregnant women in the age groups 30–34 years (3.45%) and
<20 years (3.49%) showed the lowest anti-HEV seropositivity. The seroprevalence of anti-
HEV IgM decreased with age from 2.8% in women aged 20–24 years to 0.49% in women over
Table 1. Sequences of primers for detection of hepatitis E virus.
Virus Primers Name Sequences of Primers 50!30 Gene Region in Genome Annealing temperature Size References
HEV HE361 GCRGTGGTTTCTGGGGTGAC ORF2/ORF3 5257–5276 56 C 164 bp [12]
HE364 CTGGGMYTGGTCDCGCCAAG 5420–5401
HE366 GGGYTGATTCTCAGCCCTTCGC 5278–5299 56 C 139 bp
HE363 GMYTGGTCDCGCCAAGHGGA 5416–5397
HEV 3156N AATTATGCYCAGTAYCGRGTTG ORF2 5685–5706 55 C 731 bp [13]
3157N CCCTTRTCYTGCTGMGCATTCTC 6415–6393
3158N GTWATGCTYTGCATWCATGGCT 5970–5991 55 C 348 bp
3159N AGCCGACGAAATCAATTCTGTC 6317–6296
https://doi.org/10.1371/journal.pone.0191090.t001
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34 years old. Overall, anti-HEV seropositive pregnant women showed higher mean age (28.80
±7.1) compared to HEV seronegative women (27.87±5.6), but this difference was not statisti-
cally significant (P = 0.15). While anti-HEV IgM seropositive pregnant women had signifi-
cantly lower mean age (22.45±5.26) compared to anti-HEV IgM seronegative women (27.98
±5.7) (P = 0.001).
Regarding the place of residence, the highest prevalence rates of anti-HEV IgM and anti-
HEV total antibodies were observed among pregnant women resident in Bushehr city (1.46%
and 8.75%, respectively), while Jam city had the lowest prevalence rates for anti-HEV IgM and
anti-HEV total antibodies among pregnant women in this region (0.0% and 1.8%, respec-
tively). HEV seroprevalence showed a decreasing prevalence with education level, so that preg-
nant women with a higher education level had lower seroprevalence of anti-HEV total
antibodies (1.17%) and anti-HEV IgM (0.0%) when compared to uneducated women (46.51%
and 11.63%, respectively). According to ethnicity, Afghan women had the highest seropositiv-
ity (68.0% for anti-HEV total antibodies and 16.0% for anti-HEV IgM antibody); while Arab
women showed the lowest seroprevalence rates (3.16% for anti-HEV total antibodies and 0.0%
for anti-HEV IgM). Overall, the highest rate of HEV seroprevalence was observed among
Afghan and uneducated pregnant women. In addition, the seroprevalence of anti-HEV anti-
bodies increased with the number of pregnancy, so that women with more than three pregnan-
cies showed the highest HEV seropositivity (12.7%).
The majority of HEV seropositive pregnant women were in their second trimester of preg-
nancy and had history of abortion, while, in the logistic regression analysis, none of these
parameters were significantly associated with HEV seropositivity. Anti-HEV total antibodies
were more likely to be positive in those samples that collected during November (9.62%), May
(9.62%) and January (9.57%). As for anti-HEV IgM, those samples collected during January
showed the highest seropositivity (2.6%). Nevertheless, no significant association was identi-
fied between HEV seropositivity and time of sampling.
HEV seropositivity among pregnant women was statistically associated with age, ethnicity,
place of residence, number of pregnancies and level of education. So that, low education
levels (OR: 8.48; 95% CI: 4.33–16.58; P< 0.001 for uneducated women and OR: 3.89; 95% CI:
2.18–6.97; P< 0.001 for under diploma women), Afghan (OR: 65.03; 95% CI: 22.3–189.7;
P< 0.001), residence in Bushehr city (OR: 2.09; 95% CI: 1.23–3.55; P = 0.006), age group >34
years (OR: 3.73; 95% CI: 1.74–7.99; P = 0.001) and more than three pregnancies (OR: 2.54;
95% CI: 1.48–4.36; P = 0.001) were significant predictive variables for HEV seropositivity in
pregnant women. On the other hand, illiteracy was the only risk factor associated with anti-
HEV IgM seropositivity among pregnant women (OR: 16.12; 95% CI: 4.16–62.52; P< 0.001).
The prevalence rates of anti-HEV total antibodies and anti-HEV IgM among pregnant women
grouped according to socio-demographic characteristics are shown in Tables 2 and 3,
respectively.
Discussion
HEV is known to cause acute viral hepatitis, but complications are usually self-limiting. HEV
is also known for its ability to cause severe life threatening complications in pregnant women
and their offspring [7]. Despite its importance during pregnancy, there are limited data on the
prevalence and risk factors of HEV infection among pregnant women in Iran [9]. In addition,
no data are available so far on HEV prevalence among pregnant women resident in the north-
ern shores of Persian Gulf. Therefore, we evaluated the pregnant women resident in this region
in order to determine the prevalence of HEV infection, the possible risk factors associated with
Hepatitis E virus infection among pregnant women in Iran
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Table 2. Prevalence of anti-HEV total antibodies (IgG+IgM) among pregnant women according to socio-demographic characteristics.
No. of all participants (%):
1331 (100%)
No. of HEV total Ab negative subjects
(%): 1247 (93.7%)
No. of HEV total Ab positive
subjects (%): 84 (6.3%)
Adjusted OR
(95% CI)
P-Value
Age groups (years)
<20 86 (6.5%) 83 (96.51%) 3 (3.49%) 1.0
20–24 286 (21.5%) 261 (91.26%) 25 (8.74%) 2.65 (0.78–9.0) 0.12
25–29 465 (34.9%) 443 (95.27%) 22 (4.73%) 0.52 (0.29–0.94) 0.03
30–34 290 (21.8%) 280 (95.55%) 10 (3.45%) 0.72 (0.34–1.54) 0.4
>34 204 (15.3%) 180 (88.24%) 24 (11.76%) 3.73 (1.74–7.99) 0.001
Place of residence
(city)
Borazjan 456 (34.3%) 436 (95.61%) 20 (4.39%) 1.0
Bushehr 617 (46.4%) 563 (91.25%) 54 (8.75%) 2.09 (1.23–3.55) 0.006
Ahram 147 (11.0%) 139 (94.56%) 8 (5.44%) 0.60 (0.28–1.29) 0.19
Jam 111 (8.3%) 109 (98.2%) 2 (1.8%) 0.32 (0.07–1.53) 0.15
Ethnicity
Fars 1109 (83.3%) 1065 (96.03%) 44 (3.97%) 1.0
Arab 158 (11.9%) 153 (96.84%) 5 (3.16%) 0.79 (0.31–2.03) 0.63
Afghan 50 (3.8%) 16 (32.0%) 34 (68.0%) 65.03 (22.3–189.7) 0.000
Turk 14 (1.1%) 13 (92.86%) 1 (7.14%) 0.04 (0.004–0.3) 0.002
Stage of gestation
First trimester 352 (26.4%) 332 (94.32%) 20 (5.68%) 1.0
Second trimester 260 (19.5%) 237 (91.15%) 23 (8.85%) 1.61 (0.86–3.0) 0.13
Third trimester 719 (54.0%) 678 (94.3%) 41 (5.7%) 0.62 (0.37–1.06) 0.08
Number of
pregnancies
One pregnancy 412 (31.0%) 391 (94.9%) 21 (5.1%) 1.0
Two and three
pregnancies
738 (55.4%) 698 (94.6%) 40 (5. 4%) 1.1 (0.62–1.84) 0.81
More than three
pregnancies
181 (13.6%) 158 (87.3%) 23 (12.7%) 2.54 (1.48–4.36) 0.001
History of abortion
No 633 (47.6%) 605 (95.58%) 28 (4.42%) 1.0
Yes 162 (12.2%) 153 (94.44%) 9 (5.56%) 1.27 (0.59–2.75) 0.54
Unknown 536 (40.3%) 489 (91.23%) 47 (8.77%) 1.63 (0.78–3.41) 0.19
Education
Upper diploma 171 (12.8%) 169 (98.83%) 2 (1.17%) 1.0
Diploma 623 (46.8%) 607 (97.43%) 16 (2.57%) 2.23 (0.51–9.78) 0.29
Under diploma 494 (37.1%) 448 (90.69%) 46 (9.31%) 3.89 (2.18–6.97) 0.000
Uneducated 43 (3.2%) 23 (53.49%) 20 (46.51%) 8.48 (4.33–16.58) 0.000
Month
Oct 113 (8.5%) 109 (96.46%) 4 (3.54%) 1.0
Nov 208 (15.6%) 188 (90.38%) 20 (9.62%) 0.34 (0.12–1.04) 0.06
Dec 249 (18.7%) 241 (96.79%) 8 (3.21%) 1.11 (0.37–3.75) 0.87
Jan 115 (8.6%) 104 (90.43%) 11 (9.57%) 0.35 (0.11–1.12) 0.08
Feb 207 (15.6%) 197 (95.17%) 10 (4.83%) 0.72 (0.22–2.36) 0.59
Mar 229 (17.2%) 214 (93.45%) 15 (6.55%) 0.52 (0.17–1.62) 0.26
Apr 158 (11.9%) 147 (93.04%) 11 (6.96%) 0.49 (0.15–1.58) 0.23
May 52 (3.9%) 47 (90.38%) 5 (9.62%) 0.34 (0.09–1.34) 0.12
https://doi.org/10.1371/journal.pone.0191090.t002
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Table 3. Prevalence of anti-HEV IgM among pregnant women according to socio-demographic characteristics.
No. of all participants (%):
1331 (100%)
No. of HEV IgM negative subjects
(%): 1320 (99.17%)
No. of HEV IgM positive subjects
(%): 11 (0.83%)
Adjusted OR (95%
CI)
P-
Value
Age groups (years)
<20 86 (6.5%) 84 (97.67%) 2 (2.33%) 1.0
20–24 286 (21.5%) 278 (97.2%) 8 (2.8%) 0.83 (0.17–3.97) 0.813
25–29 465 (34.9%) 465 (100.0%) 0 (0.0%) 0.00 0.993
30–34 290 (21.8%) 290 (100.0%) 0 (0.0%) 0.00 0.994
>34 204 (15.3%) 203 (99.51%) 1 (0.49%) 4.83 (0.43–54.02) 0.201
Place of residence
(city)
Borazjan 456 (34.3%) 455 (99.78%) 1 (0.22%) 1.0
Bushehr 617 (46.4%) 608 (98.54%) 9 (1.46%) 6.73 (0.85–53.35) 0.07
Ahram 147 (11.0%) 146 (99.32%) 1 (0.68%) 0.46 (0.06–3.68) 0.47
Jam 111 (8.3%) 111 (100.0%) 0 (0.0%) 0.00 0.99
Ethnicity
Fars 1109 (83.3%) 1106 (99.73%) 3 (0.27%) 1.0
Arab 158 (11.9%) 158 (100.0%) 0 (0.0%) 0.00 0.99
Afghan 50 (3.8%) 42 (84.0%) 8 (16.0%) 0.02 (0.01–0.06) 0.000
Turk 14 (1.1%) 14 (100.0%) 0 (0.0%) 0.00 0.99
Stage of gestation
First trimester 352 (26.4%) 349 (99.15%) 3 (0.85%) 1.0
Second trimester 260 (19.5%) 256 (98.46%) 4 (1.54%) 1.82 (0.4–8.19) 0.44
Third trimester 719 (54.0%) 715 (99.44%) 4 (0.56%) 0.36 (0.09–1.44) 0.15
Number of
pregnancies
One pregnancy 412 (31.0%) 408 (99.03%) 4 (0.97%)
Two and three
pregnancies
738 (55.4%) 731 (99.05%) 7 (0.95%) 0.98 (0.28–3.36) 0.97
More than three
pregnancies
181 (13.6%) 181 (100.0%) 0 (0.0%) 0.00 0.99
History of abortion
No 633 (47.6%) 629 (99.37%) 4 (0.63%)
Yes 162 (12.2%) 161 (99.38%) 1 (0.62%) 0.98 (0.11–8.8) 0.98
Unknown 536 (40.3%) 530 (98.88%) 6 (1.12%) 1.82 (0.22–15.25) 0.58
Level of education
Upper diploma 171 (12.8%) 171 (100.0%) 0 (0.0%) 1.0
Diploma 623 (46.8%) 621 (99.68%) 2 (0.32%) 0.00 0.99
Under diploma 494 (37.1%) 490 (99.19%) 4 (0.81%) 2.53 (0.46–13.9) 0.28
Uneducated 43 (3.2%) 38 (88.37%) 5 (11.63%) 16.12 (4.16–62.52) 0.00
Time of sampling
(month)
Oct 113 (8.5%) 112 (99.11%) 1 (0.89%) 1.0
Nov 208 (15.6%) 208 (100.0%) 0 (0.0%) 0.00 0.99
Dec 249 (18.7%) 248 (99.6%) 1 (0.4%) 2.21 (0.14–35.72) 0.57
Jan 115 (8.6%) 112 (97.4%) 3 (2.6%) 0.33 (0.03–3.25) 0.35
Feb 207 (15.6%) 205 (99.03%) 2 (0.97%) 0.92 (0.08–10.21) 0.94
Mar 229 (17.2%) 229 (100.0%) 0 (0.0%) 0.00 0.99
Apr 158 (11.9%) 155 (98.1%) 3 (1.9%) 0.46 (0.05–4.49) 0.51
May 52 (3.9%) 51 (98.08%) 1 (1.92%) 0.46 (0.03–7.43) 0.58
https://doi.org/10.1371/journal.pone.0191090.t003
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incidence of HEV infection and to clarify the epidemiology of HEV infection among pregnant
women in this territory.
HEV seroprevalence of 6.3% reported in the present study is higher than those reported
among pregnant women in different parts of Iran, 3.6% in Urmia [14] and 5.26% in Ahvaz
[15], but lower than those reported in Hamadan (7.4%) [16] and Gorgan (7.4%) [17]. Overall,
the prevalence of HEV among pregnant women varies from 3.6% to 7.4% in different regions
of Iran. These results demonstrate that the prevalence of HEV infection is variable even within
a country and dependent upon level of public health and hygiene of each region [9]. The
reported seroprevalence in this study is also higher than HEV seroprevalence among pregnant
women in Spain (3.6%) [18], and Mexico (5.7%) [19] but lower than those of Nile Delta
(84.3%) [20], Sudan (61.2%) [21], Ethiopia (31.6%) [22], Ghana (28.66%) [23], the United
Arab Emirates (20.0%) [24], Benin (16.19%) [25], Gabon (14.1%) [26], Turkey (12.6%) [27],
China (11.1%) [28], and France (7.74%) [29].
The seroprevalence of 0.83% for anti-HEV IgM observed in this study is in range of previ-
ous reports from different parts of Iran, 0.23% among pregnant women in Ahvaz [15], 0.9%
among general population in Shiraz [30], and 1.4% among adults in Ahvaz [31]. This seroprev-
alence is lower than that reported in Benin (1.44%) [25] but higher than those of Spain (0.67%)
[18], China (0.6%) [28], Ethiopia (0.5%) [22], and Turkey (0.0%) [27].
These variations in the prevalence of HEV infection reflect differences in the prevalence of
HEV infection in the general population, routes of transmission, risk factors, level of aware-
ness, preventive strategies, socioeconomic status and level of sanitation in different parts of the
world [8, 32]. In addition, differences in the time of sampling, number of participants or sam-
ple size, sociodemographic characteristics of study population, study period, and specificity
and sensitivity of diagnostic assays can explain these variations [8, 31].
The anti-HEV prevalence of 6.3% and anti-HEV IgM prevalence of 0.83% reported in this
study are in the range of HEV seroprevalence in the general population of Iran, 1.1% to 14.2%
for anti-HEV IgG and anti-HEV total antibodies and 0.0% to 0.9% for anti-HEV IgM [8].
These coincidences considerably indicate that the prevalence of HEV infection in a given pop-
ulation can be influenced by the burden of HEV infection in the general population.
In Iran, as the other endemic country, HEV is predominantly transmitted through contam-
ination of water supplies [8]. This mode of transmission effectively spreads HEV in the society
and is responsible for occurrence of epidemics or outbreaks of hepatitis E. While in non-
endemic countries, HEV is mainly transmitted through contamination of food supplies and
mostly appears as sporadic infection [1, 5, 8]. However, in Iran, the prevalence of HEV infec-
tion is considerably low compared to HEV prevalence among pregnant women of the other
endemic countries [9].
Our study showed that younger pregnant women were more likely to be anti-HEV IgM
seropositive as compared to older women, and the mean age of anti-HEV IgM seropositive
pregnant women was significantly lower than that of seronegative women. This is consistent
with the age distribution of HEV infection in developing countries, where HEV infection is
more prevalent among young adults [33]. The high prevalence of HEV among young popula-
tion of this territory is a cause for concern. Therefore, improvement of sewage disposal system,
public hygiene, sanitation and drinking water supply systems is required to drive down HEV
prevalence in the society. Our results in accordance with those of most studies from Iran
revealed a significant association between older ages (women over 34 years old in this study)
and higher anti-HEV IgG prevalence due to cumulative exposure to the virus over time [8, 15–
17, 31]. This finding is also in concordance with several studies from France [29], Turkey [27],
Ethiopia [22], Mexico [19] and Egypt [20], which have shown a higher prevalence of HEV
among older age groups compared to younger age groups [19, 20, 22, 27, 29].
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The results of the present study also demonstrate that uneducated women are more preva-
lent infected by HEV than educated pregnant women. This decreasing prevalence with educa-
tion level can be explained by the fact that people with lower education are less aware of HEV
infection and the possible ways of exposure to HEV and often live in poor socioeconomic and
hygiene conditions, which increase the risk of HEV transmission. The significant association
between level of education and HEV seroprevalence in this study is in agreement with the pre-
vious studies from Iran [15–17] and the other parts of the world [22, 23, 27, 34]. In contrast, a
recent study from Mexico has shown that there is no significant association between level of
education and HEV seropositivity [19].
Another risk factor associated with HEV seropositivity is ethnicity. In this study, HEV sero-
prevalence was more prevalent in Afghan than the other ethnic groups. Afghanistan is consid-
ered as a highly endemic country for HEV infection [35]. The high endemicity of HEV
infection in Afghanistan also supports the high seroprevalence of HEV infection among
Afghan immigrants. Furthermore, we found a significant association between HEV seropreva-
lence and the number of pregnancy, so that anti-HEV seroprevalence was significantly higher
among those women with more than three pregnancies. This finding is consistent with studies
done by Mamani et al [16] and Tabarraei et al [17], while some other studies do not support
this finding [14, 22, 25].
Bushehr and Jam showed the highest and the lowest rates of HEV seroprevalence, respec-
tively, as compared to the other cities in this territory. The high prevalence of HEV among
pregnant women resident in Bushehr city can be explained by this fact that Bushehr seaport is
one of the most important international ports in south of Iran with a high migration flow,
while Jam city has the lowest rate of immigration in this territory.
In our study, HEV seropositivity among pregnant women was not statistically associated
with history of abortion, stage of gestation, and time of sampling. All seropositive women had
successful childbirth, and no maternal, prenatal or neonatal complications were reported. In
some geographical regions, HEV infection follows an asymptomatic or mild course in preg-
nancy. The benign pathogenicity of HEV infection might be due to the predominance of less
virulent strains of HEV in these regions [2, 36]. With respect to the fact that genotypic pattern
of HEV in Iran is unknown, more studies are required to generalize this conclusion to Iran. In
contrast, a recent study from Sudan revealed the significant role of HEV in spontaneous abor-
tion among Sudanese pregnant women [21]. On the other hand, Rasti et al, Tabarraei et al and
Adjei et al demonstrated that HEV seropositivity among pregnant women is associated with
stage of gestation [15, 17, 23].
The strength of this study is consecutive recruitment of pregnant women, which has
increased generalizability of the results to the pregnant population of this territory. As a limita-
tion, we were not able to evaluate the possible association between socioeconomic status of
pregnant women and HEV seropositivity, because the majority of pregnant women were not
willing to answer this question. Some studies from Turkey and India have reported a signifi-
cant association between socio-economic status and HEV seropositivity, so that pregnant
women with low socioeconomic status tended to be more positive for HEV infection [27, 34].
In contrast, a recent study from Mexico showed that HEV seroprevalence was not associated
with socioeconomic status of pregnant women [19]. Furthermore, we could not determine the
genotypic pattern of HEV infection among pregnant women. Since none of the pregnant
women had HEV viremia, and HEV RNA did not find in any of the samples. HEV viremia is
short-lived. In stool, however, the virus can be detected for a longer period of time than in
serum [33, 4]. Nevertheless, we did not try to isolate HEV from the stool specimens. This is
another limitation of the current study. Therefore, the molecular epidemiology of HEV infec-
tion remained unknown in this territory.
Hepatitis E virus infection among pregnant women in Iran
PLOS ONE | https://doi.org/10.1371/journal.pone.0191090 January 12, 2018 9 / 12
Conclusion
The northern shores of Persian Gulf in Iran, with HEV seroprevalence of 6.3%, can be classi-
fied as an endemic geographical region for hepatitis E, and residents of Bushehr city, Afghan
immigrants and uneducated women are the main at-risk populations. At present, there are no
data on the probable effects of hepatitis E on pregnancy outcomes in terms of maternal and
prenatal mortality in Iran. In addition, the circulating HEV genotypes in the pregnant popula-
tion of Iran need to be determined in order to characterize the epidemiological patterns of
HEV in terms of pathogenicity and severity.
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